Mulvihill, NY
Kristen Michelle Mulvihill, Dix Hills, NY US
Patent application number | Description | Published |
---|---|---|
20120041202 | Preparation of C-Pyrazine-Methylamines - A process for preparing a compound of formula (I) or a salt thereof: (I) wherein R1 is H or optionally substituted aryl or heteroaryl; comprising reacting 2,3-dichloropyrazine with a suitable diaryl imine followed by hydrolysis. | 02-16-2012 |
20120077979 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 03-29-2012 |
20130123501 | PROCESS FOR THE PREPARATION OF THE COMPOUND OSI-906 - Process for preparing the tyrosine kinase inhibitor OSI-906 comprises coupling Compound (2) with Compound (6) under specified conditions. | 05-16-2013 |
20130165651 | FUSED BICYCLIC mTOR INHIBITORS - Compounds represented by Formula (I) | 06-27-2013 |
20130261306 | PREPARATION OF C-PYRAZINE-METHYLAMINES - A process for preparing a compound of formula (I) or a salt thereof: (I) wherein R1 is H or optionally substituted aryl or heteroaryl; comprising reacting 2,3-dichloropyrazine with a suitable diaryl imine followed by hydrolysis. | 10-03-2013 |
Kristen Michelle Mulvihill, Melville, NY US
Patent application number | Description | Published |
---|---|---|
20110015197 | mTOR INHIBITOR SALT FORMS - Salt forms of mTOR inhibitors of the Formula (I): | 01-20-2011 |
20110190496 | FUSED BICYCLIC mTOR INHIBITORS - Compounds represented by Formula (I) | 08-04-2011 |
20110218183 | Fused Bicyclic mTOR Inhibitors - Compounds represented by Formula (I) | 09-08-2011 |
Kristen Michelle Mulvihill, Oix Hills, NY US
Patent application number | Description | Published |
---|---|---|
20120196847 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 08-02-2012 |
Kristen Michelle Mulvihill, E. Northport, NY US
Patent application number | Description | Published |
---|---|---|
20090118499 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 05-07-2009 |
20090163468 | Fused Bicyclic mTor Inhibitors - Compounds represented by Formula (I) | 06-25-2009 |
20090325928 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 12-31-2009 |
20100099679 | FUSED BICYCLIC mTOR INHIBITORS - Compounds represented by Formula (I) | 04-22-2010 |
Mark J. Mulvihill, Melville, NY US
Patent application number | Description | Published |
---|---|---|
20110046144 | IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS - Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein X | 02-24-2011 |
20110224191 | Substituted Pyrrolo[2,3-b]-Pyridines and -Pyrazines - Compounds of Formula I, as shown below and defined herein: (I) pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by Ron and/or Met. | 09-15-2011 |
20110281888 | Fused Bicyclic Kinase Inhibitors - Compounds of Formula I, as shown below and defined herein: | 11-17-2011 |
20120046267 | 7-AMINOFUROPYRIDINE DERIVATIVES - Compounds of Formula 1, as shown below and defined herein: | 02-23-2012 |
Mark J. Mulvihill, East Northport, NY US
Patent application number | Description | Published |
---|---|---|
20090197862 | 2-AMINOPYRIDINE KINASE INHIBITORS - 2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition. | 08-06-2009 |
20090197864 | Furo- and Thieno [3,2-c] Pyridines - Furo[3,2-c]Pyridine and Thieno[3,2-c]pyridine compounds of Formula I, and pharmaceutically acceptable salts thereof, preparation, intermediates, pharmaceutical compositions, and use, such as in disease treatment, including cancers, including conditions in which EMT is involved, including conditions mediated by protein kinase activity such as RON and/or MET. | 08-06-2009 |
20090286768 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES - Fused pyridine-based bicyclic compounds having the structure of Formula I, as defined herein, pharmaceutically acceptable salts thereof, preparation, compositions, and disease treatment therewith. This abstract does not define or limit the invention. | 11-19-2009 |
Mark J. Mulvihill, Farmingdale, NY US
Patent application number | Description | Published |
---|---|---|
20080267957 | Combination cancer therapy - Methods and compositions for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially (a) a therapeutically effective amount of an anti-cancer agent and (b) an IGF1R inhibitor compound of Formula I, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. Suitable IGF1R inhibitor may be represented by Formula I: | 10-30-2008 |
Mark J. Mulvihill, Dix Hills, NY US
Patent application number | Description | Published |
---|---|---|
20120220595 | Deuterated Tyrosine Kinase Inhibitors - Compounds of Formula I, as shown below and defined herein: enriched in deuterium, and pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by IGF-1R and/or IR. | 08-30-2012 |
20120329826 | SUBSTITUTED-5-AMINOPYRROLO/PYRAZOLOPYRIDINES - Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by RON and/or MET. | 12-27-2012 |
20130072495 | FUSED BICYCLIC KINASE INHIBITORS - Compounds of Formula I, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as but not limited to tumors driven at least in part by at least one of RON, MET, IR, IGF-1R, or ALK. This Abstract is not limiting of the invention. | 03-21-2013 |
20130190496 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 07-25-2013 |
20130253197 | FUSED BICYCLIC KINASE INHIBITORS - Compounds of Formula I, as shown below and defined herein: | 09-26-2013 |
20140088114 | FUSED BICYCLIC KINASE INHIBITORS - Compounds of Formula (I), pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of MET, RON, ALK, IR, or IGF-1R. This Abstract is not limiting of the invention. | 03-27-2014 |
Mark Joesph Mulvihill, East Northport, NY US
Patent application number | Description | Published |
---|---|---|
20090163468 | Fused Bicyclic mTor Inhibitors - Compounds represented by Formula (I) | 06-25-2009 |
Mark Joseph Mulvihill, Melville, NY US
Patent application number | Description | Published |
---|---|---|
20110190496 | FUSED BICYCLIC mTOR INHIBITORS - Compounds represented by Formula (I) | 08-04-2011 |
20110218183 | Fused Bicyclic mTOR Inhibitors - Compounds represented by Formula (I) | 09-08-2011 |
Mark Joseph Mulvihill, E. Northport, NY US
Patent application number | Description | Published |
---|---|---|
20090118499 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 05-07-2009 |
20090325928 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 12-31-2009 |
Mark Joseph Mulvihill, Oix Hills, NY US
Patent application number | Description | Published |
---|---|---|
20120196847 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 08-02-2012 |
Mark Joseph Mulvihill, East Northport, NY US
Patent application number | Description | Published |
---|---|---|
20100099679 | FUSED BICYCLIC mTOR INHIBITORS - Compounds represented by Formula (I) | 04-22-2010 |
Mark Joseph Mulvihill, Farmingdale, NY US
Patent application number | Description | Published |
---|---|---|
20080227788 | IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS - Compounds of the formula | 09-18-2008 |
20080299113 | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents - The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and an IGF1R inhibitor compound of Formula I combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and IGF1R inhibitor compound of Formula I combination with a pharmaceutically acceptable carrier. The IGF1R inhibitor is represented by Formula I: | 12-04-2008 |
Mark Joseph Mulvihill, Dix Hills, NY US
Patent application number | Description | Published |
---|---|---|
20120077979 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 03-29-2012 |
20130165651 | FUSED BICYCLIC mTOR INHIBITORS - Compounds represented by Formula (I) | 06-27-2013 |